Literature DB >> 1590680

Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.

H Lode1, C Müller, K Borner, C E Nord, P Koeppe.   

Abstract

The pharmacokinetics of cefprozil were determined with 12 volunteers (8 received cefprozil and 4 received a placebo) after oral administration of 500 mg every 12 h over an 8-day period in a randomized, double-blind, placebo-controlled design. Concentrations in serum and urine were measured by high-pressure liquid chromatography and bioassay. The pharmacokinetic parameters were calculated on the basis of an open one-compartment model. The mean maximum concentration in serum on day 1 was 11.5 +/- 2.6 mg/liter, and the time to reach maximum concentration was 122.3 +/- 30 min after administration. Bioavailability parameters (area under the concentration-time curve from zero to infinity, maximum concentration of the drug in serum, and urinary recovery) indicated an excellent absorption. No accumulation over the 8-day period was registered. Cefprozil had a short biological elimination half-life of 58 +/- 10 min and a renal clearance of 210 +/- 51 ml/min, indicating high rates of renal excretion and tubular secretion. Analysis of the fecal flora showed an ecological impact of cefprozil on the intestinal microflora, such as a moderate decrease in enterobacteria and a slight increase in enterococci, staphylococci, and bacteroides during the study. The number of all bacterial species was already normalized 4 days after the administration period. The tolerance of cefprozil proved to be excellent; only a slight and reversible increase of liver enzymes (in two volunteers), mild cephalalgia, tiredness, and soft stool were registered during the 8-day period. Cefprozil had excellent absorption, no accumulation over an 8-day period, and only a limited impact on the intestinal microflora.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1590680      PMCID: PMC189242          DOI: 10.1128/AAC.36.1.144

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  Clinical pharmacokinetics (second of two parts).

Authors:  D J Greenblatt; J Koch-Weser
Journal:  N Engl J Med       Date:  1975-11-06       Impact factor: 91.245

Review 2.  [Intestinal flora and chemotherapy].

Authors:  G Linzenmeier
Journal:  Internist (Berl)       Date:  1989-06       Impact factor: 0.743

3.  Pharmacokinetics of cefixime in the young and elderly.

Authors:  R D Faulkner; W Bohaychuk; R A Lanc; J D Haynes; R E Desjardins; A Yacobi; B M Silber
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

4.  Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

Review 5.  Pharmacokinetic properties of the cephalosporins.

Authors:  T Bergan
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  BMY 28100, a new oral cephalosporin.

Authors:  F Leitner; T A Pursiano; R E Buck; Y H Tsai; D R Chisholm; M Misiek; J V Desiderio; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

7.  The pharmacokinetic and bactericidal characteristics of oral cefixime.

Authors:  D C Brittain; B E Scully; T Hirose; H C Neu
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

8.  Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans.

Authors:  J R Koup; U C Dubach; R Brandt; R Wyss; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

9.  Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency.

Authors:  D R Guay; R C Meatherall; G K Harding; G R Brown
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

10.  Absolute bioavailability of cefixime in man.

Authors:  R D Faulkner; P Fernandez; G Lawrence; L L Sia; A J Falkowski; A I Weiss; A Yacobi; B M Silber
Journal:  J Clin Pharmacol       Date:  1988-08       Impact factor: 3.126

View more
  8 in total

Review 1.  Comparative pharmacokinetics of the new oral cephalosporins.

Authors:  H Lode; M Fassbender; T Schaberg; K Borner; P Koeppe
Journal:  Drugs       Date:  1994       Impact factor: 9.546

Review 2.  Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.

Authors:  L R Wiseman; P Benfield
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

4.  Effect of ceftibuten on the normal intestinal microflora.

Authors:  B Brismar; C Edlund; C E Nord
Journal:  Infection       Date:  1993 Nov-Dec       Impact factor: 3.553

Review 5.  Comparative microbiological activity and pharmacokinetics of cefprozil.

Authors:  R Wise
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-10       Impact factor: 3.267

6.  The initial state of the human gut microbiome determines its reshaping by antibiotics.

Authors:  Frédéric Raymond; Amin A Ouameur; Maxime Déraspe; Naeem Iqbal; Hélène Gingras; Bédis Dridi; Philippe Leprohon; Pier-Luc Plante; Richard Giroux; Ève Bérubé; Johanne Frenette; Dominique K Boudreau; Jean-Luc Simard; Isabelle Chabot; Marc-Christian Domingo; Sylvie Trottier; Maurice Boissinot; Ann Huletsky; Paul H Roy; Marc Ouellette; Michel G Bergeron; Jacques Corbeil
Journal:  ISME J       Date:  2015-09-11       Impact factor: 10.302

7.  Effects of treatment with antimicrobial agents on the human colonic microflora.

Authors:  Fatemeh Rafii; John B Sutherland; Carl E Cerniglia
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

Review 8.  Role of cephalosporins in the era of Clostridium difficile infection.

Authors:  Mark H Wilcox; James D Chalmers; Carl E Nord; Jane Freeman; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2016-09-22       Impact factor: 5.790

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.